We have been evolving our business by focusing on research and development of a family of small molecule compounds called SMTPs (stachybotrys microspora triprenyl phenols), initially discovered as a microbial metabolite at Tokyo University of Agriculture and Technology.
Our efforts have led to promising results, both in efficacy and safety, from a Phase 2a clinical trial of TMS-007, which we believe has potential to bring significant change to the global standard of care for acute ischemic stroke. We are proudly engaged in further development of TMS-007, which we have been involved since the research stage to present day.
Our research and development experience with SMTP compounds includes a series of successful experiments, detailed analyses, and thorough evaluation of evidence. This process reflects our commitment to uncovering truth within a complex landscape. In an area where traditional drug discovery approaches are becoming increasingly rare in the pharmaceutical industry, we remain dedicated to this meticulous methodology, and we believe that by refining and advancing this classic approach, we can unlock significant business opportunities.
Our robust pipeline also includes, TMS-008 for the potential treatment for acute kidney injury, and JX09, for the potential treatment for resistant hypertension, among other programs. We will continue efforts to develop these compounds for the targeted indications in which the current medical needs are not sufficiently met.
In addition, we aim to strengthen our portfolio by actively collaborating with scientists and global companies, a practice that is already in action. Through these efforts, we remain committed to delivering breakthrough pharmaceutical products to patients.
Takuro Wakabayashi
Chief Executive Officer
